drugset / Trial / NCT00726544

Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy

NCT00726544

Phase 2 Terminated 100 enrolled Archemix Corp.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this ascending-dose research study is to determine whether the administration of ARC1779 Injection improves subject's health profile by protecting the brain, heart, and kidney from damage due to formation of small blood clots in blood vessels. It will also determine the safety of ARC1779 Injection, how ARC1779 Injection enters and leaves the blood and tissue over time, and its effect on laboratory tests related to blood clotting, heart and brain function, and other body systems.

Timeline

Start
2008-12
Primary completion
2010-12
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator EGAPTIVON PEGOL Aptamer Intravenous